Preliminary, Real-world, Multicenter Experience With Omadacycline for Mycobacterium abscessus Infections

Twelve patients were treated with omadacycline (OMC) as part of a multidrug regimen for Mycobacterium abscessus. The majority of infections were of pulmonary origin (7/12; 58.3%). The median (interquartile range) duration of OMC was 6.2 (4.2-11.0) months. Clinical success occurred in 9/12 (75.0%) patients. Three patients experienced a possible adverse effect while on therapy.

Automated summary

In this study, 12 patients with Mycobacterium abscessus infection were treated with omadacycline as part of a multidrug regimen. The median duration of OMC treatment was relatively long, and overall clinical success was observed in 75% of patients, with three patients experiencing possible adverse effects.